Arcturus Therapeutics is an industry leader in the application of RNA technologies for the treatment of disease and improved quality of life. The company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. Backed by a management team with extensive experience in the discovery and development of RNA medicines, Arcturus is on the forefront of research and development of RNA delivery technologies.
Founded in 2013 and based in San Diego, Calif., Arcturus Therapeutics is poised to become an industry leader in the application of RNAi technologies for the treatment of disease and improved quality of life.Read More
Arcturus is developing RNA medicines for the treatment of rare diseases. Our lead asset is an UNA-modified, LUNAR-formulated siRNA targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.Read More
Arcturus is developing RNA medicines to treat the root-cause of disease and help patients in truly innovative way. Our current focus is on RNA medicines for the treatment of rare diseases and high unmet medical needs.Read More
Where We'll Be
BIO-Europe Spring® Conference